Antibiotics are medicines that treat bacterial infections by disrupting processes bacteria need to survive or reproduce. They exploit differences between bacterial cells and human cells—such as bacterial cell walls, ribosomes, and DNA-handling enzymes—while some also block essential metabolic reactions. The World Health Organization (WHO) estimated that bacterial antimicrobial resistance directly caused 1.27 million deaths worldwide in 2019, underscoring why understanding antibiotic action matters: it helps explain treatment choices, the emergence of resistance, and the need to use these drugs carefully.
How antibiotics exploit bacterial structural vulnerabilities
A bacterial vulnerability is a structure or biological process that a drug can disrupt more strongly in bacteria than in the patient. The National Institute of Allergy and Infectious Diseases describes antibiotics as medicines that kill bacteria or inhibit their growth; they do not treat viral infections. This selectivity is often based on features absent from human cells, or on bacterial versions of shared cellular machinery that differ enough for a drug to target.
Cell-wall synthesis: beta-lactams and glycopeptides
The bacterial cell wall gives many bacteria shape and protection against osmotic pressure. Human cells do not have this peptidoglycan wall, making its construction a useful drug target. Penicillins, cephalosporins, carbapenems, and monobactams—groups of beta-lactam antibiotics—bind penicillin-binding proteins that build and cross-link peptidoglycan. The weakened wall can fail as the bacterium grows, leading to cell death. Glycopeptides such as vancomycin also interfere with peptidoglycan assembly, but by binding building-block precursors rather than the same enzyme targets.
These drugs illustrate both the advantage and limits of selective targeting. Beta-lactams can be highly effective against susceptible bacteria, but bacterial beta-lactamase enzymes can break the drug’s beta-lactam ring. Changes to drug targets or reduced access through the bacterial envelope can also undermine treatment. The Centers for Disease Control and Prevention (CDC) identifies resistance to important beta-lactam drugs, including carbapenems, as a serious clinical concern in some pathogens.
Cell membranes: a vulnerability with narrower selectivity
Bacterial membranes control the movement of substances into and out of the cell. Polymyxins, including colistin, disrupt the outer and inner membranes of many Gram-negative bacteria, while daptomycin disrupts the membrane of susceptible Gram-positive bacteria. Because human cells also have membranes, membrane-targeting drugs require particular care: their usefulness depends on differences in membrane composition and drug access, and some can cause significant toxicity. They are generally reserved for particular infections rather than used as universal antibiotics.
How antibiotics exploit bacterial protein-making machinery
After structural targets, another major vulnerability is bacterial protein synthesis. Bacteria make proteins with 70S ribosomes, built from 30S and 50S subunits; human cytoplasmic ribosomes are 80S. This difference allows several antibiotic families to interfere with bacterial translation more selectively, although effects on human mitochondria and other adverse reactions remain possible.
30S ribosome inhibitors
Aminoglycosides, such as gentamicin, bind the 30S ribosomal subunit and can cause the cell to misread genetic instructions. Tetracyclines bind the same subunit but mainly prevent transfer RNA from bringing amino acids to the growing protein chain. These mechanisms interrupt protein production in different ways. Drug uptake, oxygen availability, bacterial species, and resistance mechanisms influence how well the medicines work; for example, reduced drug entry or altered ribosomal targets can confer resistance.
50S ribosome inhibitors
Macrolides, lincosamides, oxazolidinones, and chloramphenicol act on the 50S subunit or nearby steps in translation. Depending on the drug, they can block movement of the ribosome, prevent formation of peptide bonds, or interfere with initiation of protein synthesis. These agents are used for different organisms and clinical situations; they are not interchangeable, because each has its own spectrum, safety profile, and resistance patterns.
Resistance can arise through changes to the ribosomal binding site, enzymes that modify a drug, or transport systems that pump it out. The CDC’s antibiotic-resistance surveillance emphasizes that resistance is not a single phenomenon: its frequency varies by organism, location, and medicine. A susceptibility test can help clinicians determine whether a particular bacterium is likely to respond.
How antibiotics disrupt bacterial genetic processes and metabolism
Bacteria must copy and read their genetic material and obtain essential molecules to grow. Antibiotics can exploit differences in bacterial enzymes and metabolic pathways, extending the range of targets beyond cell walls and ribosomes. These targets connect directly to clinical practice: the suspected organism and infection site help determine which mechanism is most appropriate.
DNA replication and RNA production
Fluoroquinolones, including ciprofloxacin, inhibit bacterial DNA gyrase and topoisomerase IV, enzymes that manage DNA structure during replication. Rifamycins, including rifampin, inhibit bacterial RNA polymerase, which produces RNA from DNA templates. Blocking either process can prevent bacterial growth or survival. Mutations in the target enzymes can reduce drug binding, while other resistance mechanisms can limit the drug’s concentration inside the cell.
Folate synthesis and other metabolic targets
Some bacteria make folate, a molecule needed to produce DNA building blocks, whereas humans obtain folate from food. Sulfonamides and trimethoprim block successive steps in bacterial folate metabolism. When combined as trimethoprim-sulfamethoxazole, they can provide sequential blockade of the pathway. This is a clear example of exploiting a metabolic difference, though resistance can emerge through altered enzymes, increased pathway production, or reduced drug entry.
How bacterial defenses weaken antibiotic vulnerabilities
Antibiotic resistance is the ability of bacteria to withstand a medicine that would ordinarily inhibit or kill them. It can result from genetic mutations or from acquiring resistance genes from other bacteria. The WHO’s 2022 global antimicrobial-resistance report found that, among the bacterial pathogen–antibiotic combinations it examined, resistance exceeded 50% in a substantial share of reported combinations in many regions. These estimates vary by pathogen, drug, and country, but they show why laboratory surveillance and responsible treatment are essential.
Drug destruction, target alteration, and reduced access
Bacteria can defeat antibiotics in several recurring ways. Enzymes may inactivate a drug, as beta-lactamases do to many beta-lactams. A bacterium may alter the drug’s target so binding becomes less effective, reduce drug entry through its envelope, or use efflux pumps to expel the medicine. Some bacteria also change metabolic pathways or form biofilms—structured communities surrounded by a protective matrix—that can make infections harder to eradicate.
Real-world example: resistant infections and treatment decisions
Carbapenem-resistant Enterobacterales are an example of bacteria that can combine multiple defenses, including enzymes that break down antibiotics and changes that limit drug entry. The CDC classifies carbapenem-resistant Enterobacterales as an urgent threat in the United States. In practice, clinicians may use cultures and antimicrobial susceptibility testing to identify the organism and its likely drug response, then select treatment based on the infection, patient factors, and current guidance. This approach illustrates why a drug’s mechanism alone is not enough: the bacterium’s actual vulnerabilities must also be assessed.
Why appropriate antibiotic use protects these vulnerabilities
Antibiotic use creates selection pressure: susceptible bacteria are removed more readily, while resistant bacteria are more likely to survive and multiply. This does not mean every course inevitably causes resistance, but unnecessary use and incorrect use can increase avoidable pressure. The CDC advises taking antibiotics only when needed and exactly as prescribed. Patients should not use leftover medicines, share prescriptions, or demand antibiotics for viral illnesses such as colds and flu.
Clinicians and health systems can preserve antibiotic effectiveness through antimicrobial stewardship: choosing an appropriate drug, dose, and duration; narrowing treatment when test results become available; and preventing infections through vaccination, hygiene, and infection-control practices. Antibiotics remain indispensable, but their benefits depend on matching the drug to the pathogen while limiting unnecessary exposure.
Conclusion
Antibiotics exploit bacterial vulnerabilities in cell-wall construction, membrane integrity, protein synthesis, DNA replication, RNA production, and folate metabolism. Their selectivity comes from differences between bacteria and human cells, yet bacterial defenses—including drug-destroying enzymes, altered targets, reduced drug access, and biofilms—can weaken that advantage. With antimicrobial resistance already contributing substantially to global illness and death, preserving these medicines is a shared responsibility. Use antibiotics only under qualified medical guidance, follow the prescribed directions, and support infection prevention and antimicrobial-stewardship efforts.
Sources: World Health Organization, Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis, https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)02724-0/fulltext; World Health Organization, Global antimicrobial resistance and use surveillance system (GLASS) report 2022, https://www.who.int/publications/i/item/9789240062702; National Institute of Allergy and Infectious Diseases, Antimicrobial Resistance, https://www.niaid.nih.gov/research/antimicrobial-resistance; Centers for Disease Control and Prevention, Antibiotic Resistance Threats in the United States, 2019, https://www.cdc.gov/antimicrobial-resistance/data-research/threats/index.html; Centers for Disease Control and Prevention, About Antibiotic Use, https://www.cdc.gov/antibiotic-use/about/index.html
